News
FDA approves brensocatib for non-cystic fibrosis bronchiectasis
The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis bronchiectasis, marking the first treatment approved for this indication, according to a press release from Insmed.
FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.
With a landmark U.S. approval Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. | The FDA on Tuesday signed ...
The Food and Drug Administration (FDA) has approved Brinsupri ™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older.
PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...
Investor's Business Daily on MSN2d
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval
InsmedINSM stock hit a record high Tuesday after the Food and Drug Administration approved its drug, brensocatib, for ...
Q2 2025 Management View William H. Lewis, President, CEO & Chairman, highlighted, "Insmed is now three for three, all three ...
TipRanks on MSN1d
Insmed price target raised to $139 from $126 at Truist
Truist raised the firm’s price target on Insmed (INSM) to $139 from $126 and keeps a Buy rating on the shares. The firm is positive on the stock and updating its model following approval of BRINSUPRI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback